BioCryst Pharma

News

Two boxes of Orladeyo on a blue background

Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo

Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.

News

CSL preps filings for once-monthly antibody for HAE

Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial y

News

NICE backs BioCryst's Orladeyo for hereditary angioedema

BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland.

Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo

CSL preps filings for once-monthly antibody for HAE

NICE backs BioCryst's Orladeyo for hereditary angioedema

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks